Eargo (Nasdaq:EAR) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

EAR Stoklara Genel Bakış

Eargo, Inc., a medical device company, engages in enhancing the quality of life of people with hearing loss in the United States.

Şirket hakkında

EAR temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Risk Analizi

Kazançlar son 5 yılda yılda 35.8% oranında azaldı

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( $53M )

Eargo, Inc. Rakipler

Owlet

NYSE:OWLT

US$68.5m

Cytosorbents

NasdaqCM:CTSO

US$54.4m

Medinotec

OTCPK:MDNC

US$58.7m

Accelerate Diagnostics

NasdaqCM:AXDX

US$45.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Eargo
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.57
52 Haftanın En Yüksek Seviyesi	US$7.52
52 Haftanın En Düşük Seviyesi	US$1.47
Beta	1.48
11 Aylık Değişim	-3.75%
3 Aylık Değişim	0.62%
1 Yıllık Değişim	-64.31%
33 Yıllık Değişim	-99.80%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-99.62%

Son Haberler & Güncellemeler

Recent updates

Eargo: Straining To Be Heard

Aug 30

Eargo jumps 77% following FDA rule on OTC hearing aids

Aug 16

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Aug 08

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

Jul 10

Eargo: I Am Slowly Starting To Listen

May 06

What Kind Of Investors Own Most Of Eargo, Inc. (NASDAQ:EAR)?

Jan 16

Eargo trades high afte hours on strong Q4 revenue, gross systems shipped

Jan 11

Eargo: A Word Of Caution

Dec 15

Eargo beats on revenue

Nov 19

Hissedar Getirileri

	EAR	US Medical Equipment	US Pazar
7D	-2.7%	0.2%	-1.6%
1Y	-64.3%	25.8%	30.8%

Getiri vs. Endüstri: EAR geçen yıl % 25.8 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: EAR geçen yıl % 30.8 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is EAR's price volatile compared to industry and market?
EAR volatility
EAR Average Weekly Movement	2.7%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: EAR son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: EAR 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 11% dan 3% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2010	243	Bill Brownie	eargo.com

Eargo, Inc. Temel Bilgiler Özeti

Eargo'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
EAR temel i̇stati̇sti̇kler
Piyasa değeri	US$53.39m
Kazançlar(TTM)	-US$108.17m
Gelir(TTM)	US$41.11m

1.3x

P/S Oranı

-0.5x

F/K Oranı

EAR aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
EAR gelir tablosu (TTM)
Gelir	US$41.11m
Gelir Maliyeti	US$23.86m
Brüt Kâr	US$17.25m
Diğer Giderler	US$125.42m
Kazançlar	-US$108.17m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-5.21
Brüt Marj	41.95%
Net Kâr Marjı	-263.14%
Borç/Özkaynak Oranı	0%

EAR uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company has been acquired

EAR Stoklara Genel Bakış

Ödüller

Risk Analizi

Eargo, Inc. Rakipler

NYSE:OWLT

US$68.5m

NasdaqCM:CTSO

US$54.4m

OTCPK:MDNC

US$58.7m

NasdaqCM:AXDX

US$45.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Eargo Files Form 15

Eargo, Inc.(NasdaqGS:EAR) dropped from NASDAQ Composite Index

Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

Eargo, Inc. Announces Chief Financial Officer Changes, Effective from January 5, 2024

Patient Square Capital, LP entered into an agreement to acquire remaining 23.8% stake in Eargo, Inc. (NasdaqGS:EAR) for $13 million.

Patient Square Capital, LP entered into an agreement to acquire remaining 23.8% stake in Eargo, Inc. (NasdaqGS:EAR) for $13 million.

Recent updates

Eargo Files Form 15

Eargo, Inc.(NasdaqGS:EAR) dropped from NASDAQ Composite Index

Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

Eargo, Inc. Announces Chief Financial Officer Changes, Effective from January 5, 2024

Patient Square Capital, LP entered into an agreement to acquire remaining 23.8% stake in Eargo, Inc. (NasdaqGS:EAR) for $13 million.

Patient Square Capital, LP entered into an agreement to acquire remaining 23.8% stake in Eargo, Inc. (NasdaqGS:EAR) for $13 million.

Eargo, Inc. to Report Q1, 2023 Results on May 11, 2023

Nasdaq Confirms Eargo’s Minimum Bid Price Deficiency Is Cured

Hearing Wellness Pioneer Eargo Launches Eargo 7, Its Most Revolutionary Device Yet, at CES

Nasdaq Grants 180 Calendar Days to Eargo, Inc. to Regain Compliance

Less than half of directors are independent

Eargo, Inc. Announces Board Changes

Eargo, Inc. Announces the Appointment of Donald Spence to Its Board of Directors

Eargo, Inc. has completed a Follow-on Equity Offering in the amount of $187.5 million.

Independent Director exercised options to buy US$273k worth of stock.

Eargo Receives Non-Compliance Notice From Nasdaq

Eargo Receives a Non-Compliance Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC

Price target decreased to US$2.00

Third quarter 2022 earnings released: US$1.29 loss per share (vs US$2.02 loss in 3Q 2021)

Eargo, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Eargo: Straining To Be Heard

Eargo jumps 77% following FDA rule on OTC hearing aids

Price target decreased to US$2.00

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Eargo, Inc., Annual General Meeting, Oct 12, 2022

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Eargo, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Eargo completes $100M senior secured convertible notes issuance

Eargo, Inc.(NasdaqGS:EAR) dropped from Russell 2000 Growth Index

Eargo Receives a Letter from the Nasdaq Stock Market

Eargo Announces Receipt of Nasdaq Non-Compliance Letter

Eargo, Inc. announced delayed 10-Q filing

Eargo, Inc. announced delayed annual 10-K filing

Eargo, Inc. Launches Eargo 6 with Sound Adjust for Effortless Hearing

Eargo: A Binary Play On Hearing Loss

Price target decreased to US$10.50

Eargo Receives Notice from Nasdaq Stating Non Compliance with Listing Rule 5250(C)(1)

Eargo Is A High Risk 'Option' With High Potential

Eargo, Inc. Withdraws Financial Guidance for the Fiscal Year Ending December 31, 2021

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.50 loss per share (vs US$24.11 loss in 2Q 2020)

Eargo, Inc. Provides Financial Guidance for the Year 2021

Independent Director Geoffrey Pardo has left the company

Eargo Launches Eargo 5 Hearing Aid with Sound Match™ Technology

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

Chief Financial Officer notifies of intention to sell stock

Eargo, Inc.(NasdaqGS:EAR) dropped from Russell 3000E Value Index

Independent Director Juliet Bakker has left the company

Consensus EPS estimates increase to -US$1.00

First quarter 2021 earnings released: US$3.56 loss per share (vs US$33.52 loss in 1Q 2020)

Eargo, Inc. Increases Earnings Guidance for Full Year 2021

Eargo: I Am Slowly Starting To Listen

Independent Director notifies of intention to sell stock

Full year 2020 earnings released: US$3.80 loss per share (vs US$57.82 loss in FY 2019)

Analysts update estimates

Revenue and earnings beat expectations

Full year 2020 earnings released: US$3.80 loss per share (vs US$57.82 loss in FY 2019)